Our Blueprint

An interview with Amy Monpara and Rahul Kalathiya, Senior Medical Science Liaisons Across our organization, teams work together in pursuit of a common goal to…

Mast cell activation syndromes (MCAS) are a group of disorders characterized by the accumulation and/or increased activation of mast cells and release of various mediators…

Since our company’s inception in 2011, we’ve worked to bring innovative medicines to patients in need of new treatment options, including those living with a…

Every disease has a story, including its natural history, clinical presentation, signs and symptoms, and effect on a person’s quality of life. While these factors…

There is an old adage in medicine: “When you hear hoofbeats, think horses, not zebras.” In other words, think of common illnesses when evaluating patients…

Sharing dinner every night with family. Adapting to a new culture. Recovering from the unimaginable with the help of your dog. So often, it is…

The Women’s Edge, a non-profit dedicated to advancing women in leadership, and the Boston Globe Magazine have named Blueprint Medicines one of the Top 100…

We knew that a pattern existed, but no one was seeing it. Occurring in about 32,000 people in the United States, systemic mastocytosis is a…

Precision medicine is a term that is used a lot in the biotech industry. Precision medicine hopes to deliver dramatically better and safer treatments by…

Years of intentional work to diversify Blueprint Medicines’ leadership is being recognized. A report from the Eos Foundation found Blueprint Medicines was one of the…

Rare Disease Day is a very important reminder of the struggles faced by those living with rare conditions across the world, including their family and…

Since early in our company’s history, we’ve been deeply committed to advancing care for systemic mastocytosis as we aim to address unmet patient needs. This…

At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy…

Originally published on MassBio.org December 20, 2021 At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011.…

Last week, we announced that Jeff Albers, our Chief Executive Officer (CEO), has decided to step down and move into the position of Executive Chairman,…

Receiving a timely diagnosis is difficult for many patients living with a rare disease. These challenges are particularly significant for systemic mastocytosis (SM), a rare…

At Blueprint Medicines, we believe diversity is a core strength of our business.  By drawing upon a range of backgrounds, experiences and perspectives, we strengthen…

This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…

With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…

Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…

Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…

Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…